Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
September 01 2022 - 8:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced it has joined the Human
Proteome Organization (HUPO) Industrial Advisory Board (IAB).
Since its creation in 2006, the HUPO IAB has comprised industry
leaders in the field of proteomics. As a member company, Nautilus
will serve as an influential voice providing valuable input on
technology and product innovation to the HUPO Council and its
Executive Committee, as well as on industry trends relevant to HUPO
and its pharmaceutical and biotechnology members and partners. The
globally active committee supports academic and industrial leaders
driving the development of innovative proteomics technologies and
standards.
“We are delighted to join the HUPO Industrial Advisory Board and
to more broadly contribute to the proteomics community,” said Parag
Mallick, Ph.D., co-founder and Chief Scientist of Nautilus.
“Nautilus is looking forward to participating as a Gold Sponsor of
the 2022 HUPO World Congress, the premier international conference
for proteomics.”
About Nautilus Biotechnology, Inc.With its
corporate headquarters in Seattle and its research and development
headquarters in the San Francisco Bay Area, Nautilus is a
development stage life sciences company creating a platform
technology for quantifying and unlocking the complexity of the
proteome. Nautilus’ mission is to transform the field of proteomics
by democratizing access to the proteome and enabling fundamental
advancements across human health and medicine. To learn more about
Nautilus, visit www.nautilus.bio.
Media Contactpress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Sep 2023 to Sep 2024